Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Emepelle is a line of topical cosmeceutical products developed by Biopelle specifically to address Estrogen Deficient Skin (EDS) in perimenopausal and menopausal women. The core active ingredient is MEP Technology (Methyl Estradiolpropanoate), a non-hormonal small molecule that targets estrogen receptors in the skin. By activating these receptors, Emepelle helps restore skin function, improving hydration, firmness, and luminosity while reducing the appearance of fine lines and wrinkles. MEP Technology is designed to be metabolized in the skin to an inactive form, preventing systemic hormonal effects and making it a safe alternative to traditional hormone replacement therapy for dermatological concerns.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Emepelle.